1. Home
  2. BMRN

BMRN

BioMarin Pharmaceutical Inc.

Logo BioMarin Pharmaceutical Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Founded: 1996 Country:
United States
United States
Employees: N/A City: NOVATO
Market Cap: 17.5B IPO Year: 1999
Target Price: $108.28 AVG Volume (30 days): 1.4M
Analyst Decision: Buy Number of Analysts: 19
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.87 EPS Growth: 16.00
52 Week Low/High: $76.02 - $100.38 Next Earning Date: 04-24-2024
Revenue: $2,419,226,000 Revenue Growth: 15.42%
Revenue Growth (this year): 16.4% Revenue Growth (next year): 14.70%

Share on Social Networks:

Stock Insider Trading Activity of BioMarin Pharmaceutical Inc. (BMRN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Apr 11 '24 Sell $90.99 20,000 $1,819,800.00 474,994 SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Apr 11 '24 Sell $91.26 20,000 $1,825,200.00 474,994 SEC Form 4
Burkhart Erin BMRN GVP, Chief Accounting Officer Apr 10 '24 Sell $90.00 2,286 $205,740.00 16,156 SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Mar 5 '24 Sell $85.51 1,000 $85,510.00 561,203 SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Mar 5 '24 Sell $86.71 1,000 $86,713.00 560,203 SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Jan 18 '24 Sell $89.77 15,000 $1,346,550.00 419,602 SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Jan 18 '24 Sell $88.28 15,000 $1,324,200.00 419,602 SEC Form 4
BIENAIME JEAN JACQUES BMRN Director Dec 21 '23 Sell $93.99 10,000 $939,900.00 425,112 SEC Form 4
Davis George Eric BMRN EVP, Chief Legal Officer Dec 13 '23 Sell $95.30 13,764 $1,311,709.20 55,710 SEC Form 4